Canaccord Genuity cuts Clinuvel price target 66% to A$9.52
Canaccord Genuity cut its price target for Clinuvel Pharmaceuticals by 66% to A$9.52 per share, TradingView News reports.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.